Verve Therapeutics Inc (VERV)
$5.48
Live
Performance
- $5.47$5.63$5.48
0.18%
Downside
Day's Volatility :2.76%
Upside
2.58%
- $4.31$20.12$5.48
21.44%
Downside
52 Weeks Volatility :78.6%
Upside
72.76%
Returns
| Period | Verve Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -21.31% | 3.6% | 0.0% |
6 Months | -18.23% | 10.2% | 0.0% |
1 Year | -38.39% | 19.6% | 0.0% |
3 Years | -87.15% | 16.8% | -23.0% |
Highlights
Market Capitalization | 462.0M |
Book Value | $6.46 |
Earnings Per Share (EPS) | -2.59 |
Wall Street Target Price | 25.13 |
Profit Margin | 0.0% |
Operating Margin TTM | -879.24% |
Return On Assets TTM | -21.51% |
Return On Equity TTM | -38.1% |
Revenue TTM | 20.6M |
Revenue Per Share TTM | 0.28 |
Quarterly Revenue Growth YOY | 219.70000000000002% |
Gross Profit TTM | -128.2M |
EBITDA | -215.7M |
Diluted Eps TTM | -2.59 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.62 |
EPS Estimate Next Year | -2.95 |
EPS Estimate Current Quarter | -0.68 |
EPS Estimate Next Quarter | -0.71 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 358.58%
Technicals Summary
Sell
Neutral
Buy
Verve Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Verve Therapeutics Inc | 12.55% | -18.23% | -38.39% | -87.15% | -87.72% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Verve Therapeutics Inc | 2.34 | NA | NA | -2.62 | -0.38 | -0.22 | NA | 6.46 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Verve Therapeutics Inc | Buy | $462.0M | -87.72% | 2.34 | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Verve Therapeutics Inc
Increasing Revenue
Revenue is up for the last 8 quarters, 929.0K → 6.69M (in $), with an average increase of 23.7% per quarter
Decreasing Net Profit
Netprofit is down for the last 4 quarters, -45.75M → -49.80M (in $), with an average decrease of 2.9% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 122.0%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 132.0%
Institutional Holdings
Alphabet Inc
14.59%BlackRock Inc
7.82%Vanguard Group Inc
6.22%T. Rowe Price Investment Management,Inc.
5.35%Millennium Management LLC
4.57%State Street Corp
3.96%
Company Information
verve therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease. the company brings together human genetics analysis and gene editing – two of the biggest breakthroughs in 21st century biomedicine – to develop transformative therapies for coronary heart disease. verve is developing medicines, administered once in life, to safely edit the genome of adults to permanently lower ldl cholesterol and triglyceride levels and thereby treat coronary heart disease. founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, verve is backed by a top-tier syndicate of investors, including gv (formerly google ventures), arch venture partners, f-prime capital, biomatics capital, wellington management, casdin capital, and partners innovation fund. the company was recognized as a "2020 best places to work" by the boston business journal. verve is headquartered in cambridge, massachusetts.
Organization | Verve Therapeutics Inc |
Employees | 255 |
CEO | Dr. Sekar Kathiresan M.D. |
Industry | Services |
